Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis
Open Access
- 17 June 2020
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (11) , 2813-2820
Abstract
Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an interleukin‐6 receptor antagonist, may be beneficial for severe COVID‐19, when cytokine storm is suspected. This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48, and 72 hours, and 7, 14, and 28 days post‐tocilizumab, are reported. Patients were evaluated by baseline pre‐tocilizumab oxygenation status and changes in proinflammatory markers within 7 days post‐tocilizumab are reported. Sixty‐six patients received tocilizumab at a mean dose of 724 mg (7.4 mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c‐reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID‐19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population.Keywords
This publication has 9 references indexed in Scilit:
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)Microorganisms, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences, 2020
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)Clinical Infectious Diseases, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)Intensive Care Medicine, 2020
- Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)Chinese Medical Journal, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020